Role of physician specialties to close gaps in the care cascade of hepatitis C: Evidence from paid claims in the United States from 2010 to 2016

[1]  S. Marx,et al.  Role of physician specialties to close gaps in the care cascade of hepatitis C: Evidence from paid claims in the United States from 2010 to 2016 , 2018 .

[2]  P. Sullivan,et al.  Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Latkin,et al.  Public health clinic‐based hepatitis C testing and linkage to care in baltimore , 2016, Journal of viral hepatitis.

[4]  B. Linas,et al.  Eighteen‐ to 30‐year‐olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission , 2016, Journal of viral hepatitis.

[5]  P. Marcellin,et al.  Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials , 2015, Hepatology.

[6]  S. Zeuzem,et al.  P0873 : Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has minimal impact on health-related quality of life (HRQOL) compared with placebo during 12-week treatment in treatment-naïve adults with chronic Hepatitis C (CHC) , 2015 .

[7]  S. Schaeffer,et al.  Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics. , 2015, Annals of hepatology.

[8]  L. Gerber,et al.  Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  C. Umscheid,et al.  The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis , 2014, PloS one.

[10]  P. Marcellin,et al.  P1324 LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL , 2014 .

[11]  M. Stepanova,et al.  Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). , 2014, Journal of hepatology.

[12]  K. Mullen,et al.  The disposition of hepatitis C antibody‐positive patients in an urban hospital , 2009, Journal of viral hepatitis.

[13]  D. Nelson,et al.  Outcomes of a Hepatitis C Screening Program at a Large Urban VA Medical Center , 2008, Journal of clinical gastroenterology.